In a recent study using second-generation CD22 CAR-T cells, whereas most patients with B-ALL previously failed CD19 CAR-T therapy, the use of CD22 CAR-T cells resulted in CR rates of 73% (11/15) among patients who received ≥ 1 × 106 CD22-CAR-T cells/kg16. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.